Clinical Trials Logo

Clinical Trial Summary

To determine whether UK-390,957 is a safe treatment for premature ejaculation.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00219609
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2/Phase 3
Start date January 2005
Completion date March 2006

See also
  Status Clinical Trial Phase
Completed NCT01021670 - An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride Phase 4
Completed NCT00210613 - A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation Phase 3
Completed NCT00211107 - A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation. Phase 3
Completed NCT00219635 - Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation Phase 2/Phase 3
Terminated NCT02918227 - Exploration of Ejaculation Changing Mechanism After Surgery for Benign Prostatic Hyperplasia N/A
Completed NCT00219583 - Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation Phase 2/Phase 3
Completed NCT00143117 - Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation Phase 2/Phase 3
Completed NCT01366664 - A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin Phase 1
Completed NCT01230762 - An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation Phase 3
Completed NCT00211094 - A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation Phase 3